# A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

> **NCT05995275** · PHASE1,PHASE2 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 351 (actual)

## Conditions studied

- Smallpox
- Mpox

## Interventions

- **BIOLOGICAL:** mRNA-1769
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05995275
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-15
- **Primary completion:** 2025-07-08
- **Final completion:** 2025-07-08
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05995275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05995275, "A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05995275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*